#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukaemia Acute myeloid leukaemia (in remission) Dermatitis Hyperinsulinism Atypical haemolytic uraemic syndrome Angiosarcoma recurrent Candida infection General anaesthesia Adult T-cell lymphoma/leukaemia refractory Hyperoxaluria Exudative retinopathy Leukoencephalopathy Phenylketonuria Retinitis pigmentosa Cystic fibrosis More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis – Basic Information Focal segmental glomerulosclerosis – Diagnostics Mast cell activation syndrome Haemophilia B without inhibitors – Diagnostics Cytokine release syndrome – Life with Disease Haemophagocytic lymphohistiocytosis – Life with Disease Brain stem glioma – Basic Information Congenital generalised lipodystrophy – Life with Disease Idiopathic pulmonary fibrosis – Trials in Disease Langerhans’ cell histiocytosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sonelokimab Mrna-3210 Saxagliptin Palmidrol Tigulixostat Tiaprofenic Acid ALE.P03 Mometasone Lixudebart Oritavancin Dolutegravir Fipaxalparant GEN1078 Poractant Alfa Feladilimab Bictegravir Enomimeran Poloxamer 407 Isatuximab C1 Esterase Inhibitor (Human) More therapies…

    Learn about Your Condition

    Encephalitis autoimmune Inner ear disorder Hydrocele Undifferentiated sarcoma Myxoid liposarcoma Cerebral haemorrhage Morning sickness Hypoaesthesia Right ventricular dysfunction Breast cancer stage I Growth hormone deficiency Neuroblastoma recurrent Anogenital warts Premature baby Axial spondyloarthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cognitive disorder

  • Comparison of Three PET Tau Tracers ([18F]RO948, [18F]PI2620, and [18F]MK-6240) in People with Cognitive Impairment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Cognitive disorder
    Investigated Drugs:
    • 2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3′,4′-D]Pyrrole
    • Izaflortaucipir (18F)
    • Florquinitau (18F)
    Spain

  • Study on the Accuracy of Tau PET ([18F]RO6958948) and Vizamyl (Flutemetamol 18F) in Diagnosing Mild Cognitive Symptoms and Risk of Alzheimer’s Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Progressive supranuclear palsy
    • Dementia with Lewy bodies
    • Prodromal Alzheimer’s disease
    Investigated Drugs:
    • 2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3′,4′-D]Pyrrole
    • Flutemetamol (18F)
    Sweden

  • Study on the Safety and Effects of NTRX-07 for Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer’s Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    • Cognitive disorder
    Investigated Drugs:
    • (3-BENZYL-3-METHYL-2,3-DIHYDROBENZOFURAN-6- YL)(PIPERIDIN-1-YL)METHANONE
    Czechia Hungary Poland

  • Study of Gadobutrol for MRI in Adults with Cerebrospinal Fluid Disorders, Including Hydrocephalus and Brain Tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hydrocephalus
    • Central nervous system neoplasm
    • Cognitive disorder
    Investigated Drugs:
    • Gadobutrol
    Norway

  • Study on Lithium Carbonate for Patients with TBR1-Related Neurocognitive Disorder

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Cognitive disorder
    Investigated Drugs:
    • Lithium Carbonate
    France

  • Study on Fasudil Hydrochloride for Memory Loss Prevention in Early Alzheimer’s Disease Patients

    Recruiting

    2 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    • Cognitive disorder
    Investigated Drugs:
    • Fasudil Hydrochloride
    Norway
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!